• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Tweardy Samuel David claimed ownership of 946,974 shares (SEC Form 3)

    5/2/25 4:25:44 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVRD alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Tweardy Samuel David

    (Last) (First) (Middle)
    535 HAROLD AVENUE NE

    (Street)
    ATLANTA GA 30307

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/15/2025
    3. Issuer Name and Ticker or Trading Symbol
    Tvardi Therapeutics, Inc. [ TVRD ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 315,658 I By Trust(1)
    Common Stock 315,658 I By Trust(1)
    Common Stock 315,658 I By Trust(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Securities are directly held by a family trust of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
    /s/ Samuel D. Tweardy 05/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TVRD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVRD

    DatePrice TargetRatingAnalyst
    7/14/2025$62.00Outperform
    Raymond James
    7/11/2025$52.00Overweight
    Cantor Fitzgerald
    6/12/2025$78.00Overweight
    Piper Sandler
    5/21/2025$65.00Outperform
    Oppenheimer
    5/15/2025$55.00Buy
    BTIG Research
    More analyst ratings

    $TVRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

    Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company

    8/21/25 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

    On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway anticipated to be sufficient to fund operations into Q4 2026 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for patients with idiopathic

    8/14/25 4:01:00 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

    Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 60 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company fo

    7/15/25 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Tvardi Therapeutics with a new price target

    Raymond James initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $62.00

    7/14/25 8:56:16 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Tvardi Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $52.00

    7/11/25 8:16:19 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Tvardi Therapeutics with a new price target

    Piper Sandler initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $78.00

    6/12/25 7:57:03 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tweardy Samuel David disposed of 631,316 shares (SEC Form 4)

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    8/5/25 8:03:49 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hall Wallace L Jr was granted 246,756 shares (SEC Form 4)

    4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    5/2/25 6:19:16 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Wirk Shaheen was granted 439,194 shares (SEC Form 4)

    4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    5/2/25 6:12:20 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    SEC Filings

    View All

    Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    8/14/25 4:31:59 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tvardi Therapeutics Inc.

    10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    8/14/25 4:10:53 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tvardi Therapeutics Inc.

    SCHEDULE 13G - Tvardi Therapeutics, Inc. (0001346830) (Subject)

    8/8/25 4:30:09 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care